Skip to main content
MEDS
NASDAQ Trade & Services

DataMeds Acquires Helomics for $1.5M in Stock and Convertible Note with Full-Ratchet Anti-Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Neutral
Importance info
8
Price
$6.12
Mkt Cap
$5.142M
52W Low
$0.823
52W High
$75
52W Position info
644% above low
Off High info
92% below high
Rel. Volume info
44× avg
Market data snapshot near publication time

MEDS has more than doubled off its 52-week low of $0.823 on elevated volume (44× avg).

Summary

DataMeds AI acquired Helomics from Axe Compute for 636,328 shares (19.99% of outstanding) plus a $1.36M convertible note at $1.00/share with full-ratchet anti-dilution. The deal brings a CLIA/CAP-certified oncology lab and $1.5M cash, but the note's reset provisions could amplify future dilution.


Key Events · M&A and Partnerships · MEDS

  • Helomics Acquisition Completed

    DataMeds acquired 100% of Helomics Corporation from Axe Compute on September 11, 2026, gaining a CLIA/CAP-certified AI cancer diagnostics lab and precision oncology CRO business.

  • Consideration: 19.99% Dilution Plus Note

    Purchase price was 636,328 shares (19.99% of pre-deal outstanding) plus a $1,363,672 convertible note at $1.00/share — total stated value $1.5M. Helomics came with $1.5M cash and no third-party debt.

  • Full-Ratchet Anti-Dilution on Note

    The convertible note carries full-ratchet protection: any future equity issuance below $1.00 automatically resets the conversion price lower, potentially increasing dilution for existing shareholders.

  • Stockholder Vote Required Within 75 Days

    DataMeds must hold a stockholder meeting within 75 days to approve note conversion under Nasdaq Rule 5635(d); the note auto-converts upon approval.


Analysis · MEDS · Trade & Services

DataMeds AI completed its acquisition of Helomics, an AI cancer diagnostics lab and precision oncology CRO, from Axe Compute. The consideration includes 636,328 shares — equal to 19.99% of the company's pre-deal outstanding shares — plus a $1,363,672 convertible note at a $1.00 conversion price. The note carries a full-ratchet anti-dilution provision, meaning any future equity issuance below $1.00 automatically lowers the conversion price, which could significantly increase dilution for existing holders. Stockholder approval is required within 75 days under Nasdaq Rule 5635(d). Against the backdrop of DataMeds' going-concern warning and Nasdaq delisting risk disclosed in its August 10-Q, this acquisition adds an oncology diagnostics business with $1.5M in cash and no third-party debt, but the 19.99% share issuance and convertible note terms create meaningful overhang.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $6.12 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.82 to $75.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $0.5917 info
Change: -$0.1084 (-15%) info
Market Cap: $2.676M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.5917 info
Change: -$0.1183 (-17%) info
Market Cap: $2.676M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $0.5917 info
Change: -$0.1334 (-18%) info
Market Cap: $2.676M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.5917 info
Change: -$0.1582 (-21%) info
Market Cap: $2.676M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.5917 info
Change: -$0.2878 (-33%) info
Market Cap: $2.676M info